Senti Biosciences
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS (NCT06325748) | Senti Biosciences | 2024-04-22 |
Track Senti Biosciences automatically
Every clearance here is in the API, with alerts when new ones post.